Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855360 · ClinicalTrials.gov registry record · Phase 1
Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01855360 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants.
The verdict
NCT01855360, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of the study is to determine whether the combination of the bile acid TUDCA, and doxycycline will slow the progression of familial and senile amyloidosis.
Interventions
- DRUG Tauroursodeoxycholic Acid and Doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01855360
The ClinicalTrials.gov registry entry for NCT01855360 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tauroursodeoxycholic Acid and Doxycycline is the first listed.
NCT01855360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01855360 about?
NCT01855360 is a clinical study titled "Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy". The objective of the study is to determine whether the combination of the bile acid TUDCA, and doxycycline will slow the progression of familial and senile amyloidosis.
What is the current status of trial NCT01855360?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-06. Estimated completion is 2015-05-31.
What interventions are being tested in trial NCT01855360?
The interventions under investigation include: Tauroursodeoxycholic Acid and Doxycycline (DRUG).
Who is sponsoring clinical trial NCT01855360?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.